Vimpat · DIN 02357615 · 50 mg · tablet
Limited Use, Reason for Use code 430 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 430 required
Write on scriptReason for Use code 430 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 430
Reason for Use code 430
As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND
Patients are under the care of a physician experienced in the treatment of epilepsy.
Note: Less costly anticonvulsant therapies may include the following:
Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Vimpat · DIN 02357615
Manufacturer: UCB Canada Inc.; listing date 2012-04-24
Health Canada: Marketed since 2010-10-21 · brand VIMPAT · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 50 MG · company Ucb canada inc · schedule Prescription
Ministry pays: $0.6313 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02357615)
Source record
DIN 02357615: Vimpat
Raw flags: sec12=Y, sec3=Y
Item: 281200148; group id 431; item number 1075; lccId 00221; manufacturer id UCB
Source form: Tab; strength: 50mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.5250; ministry $0.6313
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02357615
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84272
Interchangeable products
Ach-Lacosamide · DIN 02489287 · $0.6313
Auro-Lacosamide · DIN 02475332 · $0.6313
Jamp-Lacosamide · DIN 02488388 · $0.6313
Lacosamide · DIN 02512874 · $0.6313
Mint-Lacosamide · DIN 02490544 · $0.6313
NRA-Lacosamide · DIN 02499568 · $0.6313
Pharma-Lacosamide · DIN 02478196 · $0.6313
Sandoz Lacosamide · DIN 02474670 · $0.6313
Teva-Lacosamide · DIN 02472902 · $0.6313
ZDS-Lacosamide · DIN 02487802 · $0.6313
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02357615
Shortage record checked October 6, 2026